Lactic acidosis risk factors: Difference between revisions

	Lactic acidosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Lactic acidosis from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Lactic acidosis risk factors On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Lactic acidosis risk factors All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Lactic acidosis risk factors
CDC on Lactic acidosis risk factors
Lactic acidosis risk factors in the news
Blogs on Lactic acidosis risk factors
Directions to Hospitals Treating Lactic acidosis
Risk calculators and risk factors for Lactic acidosis risk factors

Revision as of 14:22, 30 July 2021

Diabetics taking metformin and SGLT2 inhibitors, especially in conjunction with active COVID-19^[1]
Underlying sepsis
Septic, cardiogenic or haemorrhagic shock

↑ Orioli L, Hermans MP, Thissen JP, Maiter D, Vandeleene B, Yombi JC (2020). "COVID-19 in diabetic patients: Related risks and specifics of management". Ann Endocrinol (Paris). 81 (2–3): 101–109. doi:10.1016/j.ando.2020.05.001. PMC 7217100 Check |pmc= value (help). PMID 32413342 Check |pmid= value (help).

@@ Line 1: / Line 1: @@
-Diabetics taking metformin and SGLT2 inhibitors, especially in conjunction with active COVID-19<ref name="pmid32413342">{{cite journal| author=Orioli L, Hermans MP, Thissen JP, Maiter D, Vandeleene B, Yombi JC| title=COVID-19 in diabetic patients: Related risks and specifics of management. | journal=Ann Endocrinol (Paris) | year= 2020 | volume= 81 | issue= 2-3 | pages= 101-109 | pmid=32413342 | doi=10.1016/j.ando.2020.05.001 | pmc=7217100 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32413342  }} </ref>
+* Diabetics taking metformin and SGLT2 inhibitors, especially in conjunction with active COVID-19<ref name="pmid32413342">{{cite journal| author=Orioli L, Hermans MP, Thissen JP, Maiter D, Vandeleene B, Yombi JC| title=COVID-19 in diabetic patients: Related risks and specifics of management. | journal=Ann Endocrinol (Paris) | year= 2020 | volume= 81 | issue= 2-3 | pages= 101-109 | pmid=32413342 | doi=10.1016/j.ando.2020.05.001 | pmc=7217100 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32413342  }} </ref>
+* Underlying sepsis
+* Septic, cardiogenic or haemorrhagic shock
+*
 __NOTOC__
 {{Lactic acidosis}}